Biblio

Schmid CL, Streicher JM, Groer CE, Munro TA, Zhou L, Bohn LM.  2013.  Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.. J Biol Chem. 288(31):22387-98.

Jiang T, Yin F, Yao J, Brinton RD, Cadenas E.  2013.  Lipoic acid restores age-associated impairment of brain energy metabolism through the modulation of Akt/JNK signaling and PGC1α transcriptional pathway.. Aging Cell. 12(6):1021-31.

Podolsky AT, Sandweiss A, Hu J, Bilsky EJ, Cain JP, Kumirov VK, Lee YSun, Hruby VJ, Vardanyan RS, Vanderah TW.  2013.  Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.. Life Sci. 93(25-26):1010-6.

De Felice M, Melchiorri P, Ossipov MH, Vanderah TW, Porreca F, Negri L.  2012.  Mechanisms of Bv8-induced biphasic hyperalgesia: increased excitatory transmitter release and expression.. Neurosci Lett. 521(1):40-5.

Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.  2012.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.. J Neuroimmunol. 244(1-2):23-31.

Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV.  2012.  Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.. Eur J Pharmacol. 684(1-3):64-70.

Lochhead JJ, McCaffrey G, Sanchez-Covarrubias L, Finch JD, DeMarco KM, Quigley CE, Davis TP, Ronaldson PT.  2012.  Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain.. Am J Physiol Heart Circ Physiol. 302(3):H582-93.

Lee YSun, Kulkarani V, Cowell SM, Ma S-W, Davis P, Hanlon KE, Vanderah TW, Lai J, Porreca F, Vardanyan R et al..  2011.  Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.

Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma S-W, Yamamura HI, Vanderah TW, Porreca F, Lai J et al..  2011.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.

Tumati S, Roeske WR, Largent-Milnes TM, Vanderah TW, Varga EV.  2011.  Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.. J Neurosci Methods. 199(1):62-8.

Hanlon KE, Herman DS, Agnes RS, Largent-Milnes TM, Kumarasinghe IR, Ma SW, Guo W, Lee Y-S, Ossipov MH, Hruby VJ et al..  2011.  Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.. Brain Res. 1395:1-11.

Vardanyan R, Kumirov VK, Nichol GS, Davis P, Liktor-Busa E, Rankin D, Varga E, Vanderah T, Porreca F, Lai J et al..  2011.  Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.. Bioorg Med Chem. 19(20):6135-42.

Tarselli MA, Raehal KM, Brasher AK, Streicher JM, Groer CE, Cameron MD, Bohn LM, Micalizio GC.  2011.  Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain.. Nat Chem. 3(6):449-53.

Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JMiguel, Mantyh PW, Vanderah TW.  2010.  A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.. Life Sci. 86(17-18):646-53.

Yao J, Hamilton RT, Cadenas E, Brinton RDiaz.  2010.  Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence.. Biochim Biophys Acta. 1800(10):1121-6.

Streicher JM, Ren S, Herschman H, Wang Y.  2010.  MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart.. Circ Res. 106(8):1434-43.

Largent-Milnes TM, Yamamoto T, Nair P, Moulton JW, Hruby VJ, Lai J, Porreca F, Vanderah TW.  2010.  Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.. Br J Pharmacol. 161(5):986-1001.

Tumati S, Roeske WR, Largent-Milnes T, Wang R, Vanderah TW, Varga EV.  2010.  Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.. Br J Pharmacol. 161(1):51-64.

Dvorak K, Watts GS, Ramsey L, Holubec H, Payne CM, Bernstein C, Jenkins GJ, Sampliner RE, Prasad A, Garewal HS et al..  2009.  Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.. Am J Gastroenterol. 104(2):302-9.

Foy MR, Baudry M, Brinton RDiaz, Thompson RF.  2008.  Estrogen and hippocampal plasticity in rodent models.. J Alzheimers Dis. 15(4):589-603.

Tumati S, Milnes TLargent, Yamamura HI, Vanderah TW, Roeske WR, Varga EV.  2008.  Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.. Eur J Pharmacol. 601(1-3):207-8.

Vanderah TW, Largent-Milnes T, Lai J, Porreca F, Houghten RA, Menzaghi F, Wisniewski K, Stalewski J, Sueiras-Diaz J, Galyean R et al..  2008.  Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.. Eur J Pharmacol. 583(1):62-72.

Largent-Milnes TM, Guo W, Wang H-Y, Burns LH, Vanderah TW.  2008.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.. J Pain. 9(8):700-13.

Brinton RDiaz, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, Morgan TE, Pike CJ, Mack WJ, Stanczyk FZ et al..  2008.  Progesterone receptors: form and function in brain.. Front Neuroendocrinol. 29(2):313-39.

D Sparks L, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C.  2005.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.. Arch Neurol. 62(5):753-7.